Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 3, 2009, Pages 326-335

  Aglietta, Massimo ^a   Barkholt, Lisbeth ^b   Schianca, Fabrizio Carnevale ^a   Caravelli, Daniela ^a   Omazic, Brigitta ^b   Minotto, Coludia ^c   Leone, Francesco ^a   Hentschke, Patrik ^b   Bertoldero, Giovanni ^c   Capaldi, Antonio ^a   Ciccone, Giovannino ^d   Niederwieser, Dietger ^e   Ringdén, Olle ^b   Demirer, Tanner ^f  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Civic Hospital   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f ANKARA UNIVERSITY   (Turkey)

Author keywords

Adoptive immunotherapy; Allogeneic nonmyeloablative transplantation; Cell therapy; GVT; Metastatic colorectal cancer

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; IRINOTECAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXALIPLATIN; PREDNISONE; RALTITREXED; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DONOR; DONOR LYMPHOCYTE INFUSION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; EUROPE; FEMALE; HLA MATCHING; HUMAN; MALE; METASTASIS POTENTIAL; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; REDUCED INTENSITY CONDITIONING; SINGLE STRAND CONFORMATION POLYMORPHISM; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ENGRAFTMENT; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COLORECTAL NEOPLASMS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 59549091676     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.11.036     Document Type: Article

References (56)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
3. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
4. Saltz L.B., Meropol N.J., PJ Sr L., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
5. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
6. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
7. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 (2007) 2040-2048
8. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
9. Muranski P., Boni A., Wrzesinski C., et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?. Nat Clin Pract Oncol 3 (2006) 668-681
10. Foon K.A., Yannelli J., and Bhattacharya-Chatterjee M. Colorectal cancer as a model for immunotherapy. Clin Cancer Res 5 (1999) 225-236
11. Parmiani G. Tumor-infiltrating T cells-friend or foe of neoplastic cells?. N Engl J Med 353 (2005) 2640-2641
12. Rosenberg S.A. Shedding light on immunotherapy for cancer. N Engl J Med 350 (2004) 1461-1463
13. Appelbaum F.R. Hematopoietic cell transplantation as a form of immunotherapy. Int J Hematol 75 (2002) 222-227
14. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
15. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
16. Sykes M., Preffer F., McAfee S., et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353 (1999) 1755-1759
17. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
18. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
19. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343 (2000) 750-758
20. Ueno N.T., Cheng Y.C., Rondon G., et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102 (2003) 3829-3836
21. Bishop M.R., Fowler D.H., Marchigiani D., et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 22 (2004) 3886-3892
22. Demirer T., Barkholt L., Blaise D., et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 5 (2008) 256-267
23. Carnevale-Schianca F., Cignetti A., Capaldi A., et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 107 (2006) 3795-3803
24. Hentschke P., Barkholt L., Uzunel M., et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31 (2003) 253-261
25. Carnevale-Schianca F., Cignetti A., Capaldi A., et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 107 (2006) 3795-3803
26. Mickelson E., and Petersdorf E.W. Histocomaptibility. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' Hematopoietic Cell Transplantation (2004), Blackwell Pubblishing Ltd, London 31-42
27. Dykewicz C.A. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant 7 Suppl (2001) 19S-22S
28. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96 (2000) 2055-2061
29. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8 (2002) 512-520
30. Saral R., Ambinder R.F., Burns W.H., et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 99 (1983) 773-776
31. Bryant E., and Martin P.J. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' Hematopoietic Cell Transplantation (2004), Blackwell Publishing Ltd, London 234-243
32. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
33. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
34. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
35. Zetterquist H., Hentschke P., Thorne A., et al. A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplant 28 (2001) 1161-1166
36. Kojima R., Kami M., Hori A., et al. Reduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer. Transplantation 78 (2004) 1740-1746
37. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
38. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
39. Srinivasan R., Daniels J., Fusaro V., et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 34 (2006) 796-801
40. Martins S.L., St John L.S., Champlin R.E., et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104 (2004) 3429-3436
41. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
42. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9 (2003) 1144-1150
43. Sullivan K.M., Storb R., Buckner C.D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320 (1989) 828-834
44. Rezvani K., Yong A.S., Savani B.N., et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood 110 (2007) 1924-1932
45. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6 (2000) 1018-1023
46. Barkholt L., Danielsson R., Calissendorff B., et al. Indium-111-labelled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation. Transplantation 78 (2004) 697-703
47. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
48. Olson K.B., Hall T.C., Horton J., Khung C.L., and Hosley H.F. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther 6 (1965) 292-297
49. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
50. Bendandi M., Gocke C.D., Kobrin C.B., et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5 (1999) 1171-1177
51. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
52. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
53. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
54. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
55. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
56. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316